Portal de Periódicos da CAPES

Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse

1998; Elsevier BV; Volume: 30; Issue: 6 Linguagem: Inglês

10.1016/s0041-1345(98)00736-2

1873-2623

H. Chen, Sihua Qi, Da-Zhong Xu, William E. Fitzsimmons, I Bekersky, Suren N. Sehgal, Pierre Daloze,

Renal Transplantation Outcomes and Treatments

Protocols for islet transplantation have to take into account the diabetogenicity/islet toxicity of the immunosuppressive agents, namely corticosteroids and calcineurin inhibitors, most notably tacrolimus. The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen was a significant breakthrough that allowed the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year. Drawbacks include the side effects of sirolimus and the reduction in insulin independence to 50% at 3 years, the latter being attributed to prolonged tacrolimus exposure. Currently explored alternatives to tacrolimus include cyclosporine, mycophenolate mofetil, and the novel agent FTY 720. Perspectives for the near future involve the achievement of “prope tolerance” by strategies using lymphocyte-depleting antibodies (anti-thymocyte globulin, campath-1H, hOKT3γ1 [ala,ala]), or costimulatory blockade (anti-CD154 mAbs, CTLA4-Ig).